ArticleNature medicine2023
When to update COVID-19 vaccine composition.
Abstract read
In one paragraph
Article in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Integrating Genomic Data into Test-negative Designs for Estimating Lineage-specific COVID-19 Vaccine Effectiveness.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, 18 October 2023-9 March 2024.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Estimated Effectiveness of 2024-2025 COVID-19 Vaccination Against Severe COVID-19.JAMA network open · 2026Article
- Article
- Limitations of neutralizing antibody titers in COVID-19 vaccine efficacy trials and a call for additional correlates of protection.Human vaccines & immunotherapeutics · 2025Review
- Effectiveness of 2024-2025 COVID-19 Vaccination Against COVID-19 Hospitalization and Severe In-Hospital Outcomes - IVY Network, 26 Hospitals, September 1, 2024-April 30, 2025.medRxiv : the preprint server for health sciences · 2025Article
- Trans amplifying mRNA vaccine expressing consensus spike elicits broad neutralization of SARS CoV 2 variants.NPJ vaccines · 2025Article
- Multiple infections with Omicron variants increase breadth and potency of Omicron-specific neutralizing antibodies.Cell discovery · 2025Article
- Identifying adverse reactions following COVID-19 vaccination in Korea using data from active surveillance: a text mining approach.Epidemiology and health · 2025Article
- Human and hamster sera correlate well in identifying antigenic drift among SARS-CoV-2 variants, including JN.1.Journal of virology · 2024Article
- Effectiveness of Original Monovalent and Bivalent COVID-19 Vaccines Against COVID-19-Associated Hospitalization and Severe In-Hospital Outcomes Among Adults in the United States, September 2022-August 2023.Influenza and other respiratory viruses · 2024Article
- Immunogenicity and Efficacy of Combined mRNA Vaccine Against Influenza and SARS-CoV-2 in Mice Animal Models.Vaccines · 2024Article
- SARS-CoV-2 Evolution: Immune Dynamics, Omicron Specificity, and Predictive Modeling in Vaccinated Populations.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- An updated framework for SARS-CoV-2 variants reflects the unpredictability of viral evolution.Nature medicine · 2024Article
- Omicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results.Vaccines · 2024Article
- Multivalent mRNA Vaccine Elicits Broad Protection against SARS-CoV-2 Variants of Concern.Vaccines · 2024Article
- Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity - IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024.medRxiv : the preprint server for health sciences · 2024Article
- Antigenic cartography using hamster sera identifies SARS-CoV-2 JN.1 evasion seen in human XBB.1.5 booster sera.bioRxiv : the preprint server for biology · 2024Article
- SARS-CoV-2 biology and host interactions.Nature reviews. Microbiology · 2024Review
- Molecular epidemiology of SARS-CoV-2 in Northern South Africa: wastewater surveillance from January 2021 to May 2022.Frontiers in public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Rebecca Grant *Department of Epidemic and Pandemic Preparedness and Prevention, World Health Organization, Geneva, Switzerland.ORCID http://orcid.org/0000-0001-8412-8113
Jilian A Sacks *Department of Epidemic and Pandemic Preparedness and Prevention, World Health Organization, Geneva, Switzerland.ORCID http://orcid.org/0000-0003-4815-4693
Priya AbrahamIndian Council of Medical Research - National Institute of Virology, Pune, India.
Supamit ChunsuttiwatDepartment of Disease Control, Ministry of Public Health, Nonthaburi, Thailand.
Cheryl CohenCentre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.ORCID http://orcid.org/0000-0003-0376-2302
J Peter FigueroaUniversity of West Indies, Mona, Jamaica.ORCID http://orcid.org/0000-0001-8525-7099
Thomas FlemingDepartment of Biostatistics, University of Washington, Seattle, WA, USA.
Paul FineLondon School of Hygiene and Tropical Medicine, London, UK.
David GoldblattGreat Ormond Street Institute of Child Health, University College London, London, UK.ORCID http://orcid.org/0000-0002-0769-5242
Hideki HasegawaCenter for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo, Japan.ORCID http://orcid.org/0000-0002-6558-2297
C Raina MacIntryeBiosecurity Program, The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
Ziad A MemishResearch and Innovation Centre, King Saud Medical City, Ministry of Health and College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Elizabeth MillerDepartment of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
Sergio NishiokaIndependent Consultant, Brasilia, Brazil.
Amadou A SallInstitut Pasteur de Dakar, Dakar, Senegal.
Samba SowCentre for Vaccine Development, Ministry of Health, Bamako, Mali.
Oyewale TomoriAfrican Centre of Excellence for Genomics of Infectious Diseases, Redeemer's University, Ede, Nigeria.ORCID http://orcid.org/0000-0002-6959-5749
Youchun WangInstitute for Biological Product Control, National Institutes for Food and Drug Control, Beijing, China.ORCID http://orcid.org/0000-0001-9769-5141
Maria D Van KerkhoveDepartment of Epidemic and Pandemic Preparedness and Prevention, World Health Organization, Geneva, Switzerland.ORCID http://orcid.org/0000-0002-6135-0018
Marie-Ange WamboDepartment of Epidemic and Pandemic Preparedness and Prevention, World Health Organization, Geneva, Switzerland.
Homa Attar CohenDepartment of Acute Response Coordination, World Health Organization, Geneva, Switzerland.ORCID http://orcid.org/0000-0002-5848-0778
Samuel MesfinDepartment of Acute Response Coordination, World Health Organization, Geneva, Switzerland.
James R OtienoDepartment of Epidemic and Pandemic Preparedness and Prevention, World Health Organization, Geneva, Switzerland.ORCID http://orcid.org/0000-0001-9790-2307
Lorenzo SubissiDepartment of Epidemic and Pandemic Preparedness and Prevention, World Health Organization, Geneva, Switzerland.ORCID http://orcid.org/0000-0001-5147-575X
Sylvie BriandDepartment of Epidemic and Pandemic Preparedness and Prevention, World Health Organization, Geneva, Switzerland. briands@who.int.
David E WentworthInfluenza Division, US Centers for Disease Control and Prevention, Atlanta, GA, USA.
Kanta SubbaraoWHO Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0003-1713-3056
Funding
World Health Organization 001
Abstract
PubMed holds no abstract for this paper.
Indexed as
COVID-19COVID-19 VaccinesHumansCOVID-19 Vaccines
Identifiers
PMID
36807683What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.